Placulumab
- CAS No.
- 945781-29-3
- Chemical Name:
- Placulumab
- Synonyms
- Placulumab;Research Grade Placulumab
- CBNumber:
- CB28080866
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
- MSDS File:
- SDS
- TDS File:
- TDS
| FDA UNII | S80W9W569L |
|---|
Placulumab price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0629213 | Placulumab 96.84% | 945781-29-3 | 1mg | $325 | 2026-06-04 | Buy |
| ChemScene | CS-0629213 | Placulumab 96.84% | 945781-29-3 | 5mg | $975 | 2026-06-04 | Buy |
| ChemScene | CS-0629213 | Placulumab 96.84% | 945781-29-3 | 10mg | $1571 | 2026-06-04 | Buy |
| aablocks | AA0294SI | Placulumab >98% | 945781-29-3 | 1mg | $369 | 2026-06-02 | Buy |
| aablocks | AA0294SI | Placulumab >98% | 945781-29-3 | 5mg | $1035 | 2026-06-02 | Buy |
Placulumab Chemical Properties, Uses, Production
Uses
Placulumab (ART621) is an anti-TNF α monoclonal antibody. Placulumab has anti-inflammatory activity and has potential applications in inflammatory diseases such as arthritis[1].
in vivo
Placulumab (0.3, 1, 3 and 10 mg/kg; i.p.; twice weekly for 8 weeks) has effective anti-arthritis properties in Tg197 transgenic mouse model[1].
Pharmacokinetic (PK) parameters of Placulumab in cynomolgus macaques[1]
| Route | Dose (mg/kg) | Exposure AUC0-336 h (ng.h/mL) | Maximum concentration Cmax (ng/mL) | Time of maximum concentration tmax (h) | Elimination half-life t1/2 (h) | Clearance CL (mL/hr/kg) |
| Intravenous injection (Males) | 50 | 46000000 | 1320000 | 0.167 | 104 | 0.985 |
| Intravenous injection (Females) | 50 | 43300000 | 1020000 | 0.211 | 97.4 | 1.06 |
| Route | Dose (mg/kg) | Exposure AUC0-336 h (ng.h/mL) | Dose normalize exposure AUC0-336 h (norm) | Maximum concentration Cmax (ng/mL) | Time of maximum concentration tmax (h) | Elimination half-life t1/2 (h) |
| Subcutaneous injection (Males) | 0.5 | 676000 | 1350000 | 3190 | 50.0 | 120 |
| Subcutaneous injection (Females) | 0.5 | 445000 | 890000 | 2880 | 48.0 | 108 |
| Subcutaneous injection (Males) | 5 | 3940000 | 788000 | 22700 | 40.0 | 117 |
| Subcutaneous injection (Females) | 5 | 3840000 | 767000 | 23800 | 12.0 | 109 |
| Subcutaneous injection (Males) | 50 | 41600000 | 832000 | 272000 | 40.0 | 122 |
| Subcutaneous injection (Females) | 50 | 32300000 | 646000 | 212000 | 32.0 | 107 |
References
[1] Gay RD, et al. Anti-TNFα domain antibody construct CEP-37247: Full antibody functionality at half the size. MAbs. 2010 Nov-Dec;2(6):625-38. DOI:10.4161/mabs.2.6.13493
Placulumab Preparation Products And Raw materials
Raw materials
Preparation Products
Placulumab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 | 422450190@qq.com | China | 10305 | 58 |
| Biolab Reagents | 027-65279366 18108604356 | products@biolabreagent.com | China | 9864 | 58 |
| Wuhan Jingkangen Biomedical Technology Co., Ltd | 13720134139 086-15871494362 13720134139 | orders@jknbiochem.com | China | 7283 | 58 |
| Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 11963 | 58 |
| Wuhan Acumen Bio-Technology Co.,ltd | 027-027-16602739303 16602739303 | 673003916@qq.com | China | 4593 | 58 |
| Changsha Fuzhen Biotechnology Co.，LTD | 15111215862 18229892877 | 3062105966@qq.com | China | 5568 | 58 |
| Olix ( Hubei) Pharmaceutical Technology Co., Ltd | 17316404525 17316404525 | 209533805@qq.com | China | 9769 | 58 |
| Atagenix Laboratories | 027-87008169 17762441161 | info@atagenix.com | China | 9997 | 58 |
| Wuhan Maixi Biotechnology Co., Ltd | 18007167883 18007167883 | Service@mabnus.com | China | 921 | 58 |
